Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA for Injection, today announced that the company’s field force is established and will begin introducing its prestige aesthetics portfolio, including the RHA® Collection of dermal fillers, Resilient Hyaluronic Acid, and the HintMD financial technology (fintech) platform, in the United States (U.S.) in September.
Revance Commercial Launch
Revance is ready to execute its first commercial product portfolio launch with the completion of onboarding and training processes for their 100+ field force team.
The company plans to approach prestige aesthetic practices across the U.S., offering its first premium products and services, the RHA® Collection of dermal fillers, along with an integrated fintech platform, HintMD. The same commercial infrastructure is anticipated to roll out DaxibotulinumtoxinA for Injection for the treatment of glabellar lines upon FDA approval later this year. Revance has recently concluded the RHA® Collection PrevU early clinical experience education and training program for select practices ahead of the consumer launch of the RHA® Collection and plans to share observations in the near future.
“Revance is positioned to re-energize the aesthetics industry with the creation of a prestige category of innovative products and services and elevated customer and patient experiences available through select practices. Our commercial team, comprised of industry experts with decades of aesthetics and commercial experience, is now trained and in position to execute Revance’s first commercial launch,” said Dustin S. Sjuts, Chief Commercial Officer. “We are delighted to be entering the market with the RHA® Collection, the latest innovation in HA technology and an integrated fintech platform designed to transform existing payment processing ecosystems and improve both aesthetics practice economics and patient experiences, along with our lead investigational candidate DaxibotulinumtoxinA for Injection’s anticipated approval just around the corner.”
RHA® Collection of Dermal Fillers Clinical Study Results
The RHA® Collection of dermal fillers represent the latest advancement in HA filler science and are designed with a crosslinking method that preserves the hyaluronic acid network to more closely mimic natural HA found in the skin. The gels are designed to be resilient and adapt to facial movement, which may provide a natural look at rest and in motion. The safety and efficacy of RHA® dermal fillers are well established, having been demonstrated through clinical studies, which have been published and presented globally.